ScholarIQanswers from OpenAlex & ORCID
Jonathan D. Schwartz
ResearcherPublications, citations & collaboration network
Jonathan D. Schwartz is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jonathan D. Schwartz have?
ScholarIQindexed works
Jonathan D. Schwartz has 106 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jonathan D. Schwartz have?
ScholarIQcitation count
Jonathan D. Schwartz has 9,255 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jonathan D. Schwartz?
ScholarIQh-index
Jonathan D. Schwartz has an h-index of 30 in OpenAlex.
What is the i10-index of Jonathan D. Schwartz?
ScholarIQi10-index
Jonathan D. Schwartz has an i10-index of 48 in OpenAlex.
What is the ORCID of Jonathan D. Schwartz?
ScholarIQorcid
The ORCID for Jonathan D. Schwartz is on the source record.
What is the OpenAlex record for Jonathan D. Schwartz?
ScholarIQopenalex
The OpenAlex for Jonathan D. Schwartz is on the source record.
What are the most-cited papers on Jonathan D. Schwartz?
ScholarIQmost cited works
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
H. Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, G. Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae‐You Kim, David Cunningham, Philippe Rougier, Yoshito Komatsu, Jaffer A. Ajani, Michael Emig, Roberto Carlesi, David Ferry, Kumari Chandrawansa, Jonathan D. Schwartz, Atsushi Ohtsu
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs, Jiří Tomášek, Cho Jae Yong, Filip Dumitru, Rodolfo Passalacqua, Chanchal Goswami, Howard Safran, Lucas Vieira dos Santos, Giuseppe Aprile, David Ferry, Bohuslav Melichar, Mustapha Tehfé, Э. Э. Топузов, John Zalcberg, Ian Chau, William Campbell, Choondal Devan Sivanandan, Joanna Pikiel, Minori Koshiji, Yanzhi Hsu, Astra M. Liepa, Ling Gao, Jonathan D. Schwartz, Josep Tabernero
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo, Chia-Jui Yen, Ronnie T. P. Poon, Davide Pastorelli, Jean-Frédéric Blanc, Hyun Cheol Chung, Ari David Baron, Túlio Pfiffer, Takuji Okusaka, Kateřina Kubáčková, Jörg Trojan, Javier Sastre, Ian Chau, Shao-Chun Chang, Paolo Abada, Ling Yang, Jonathan D. Schwartz, Masatoshi Kudo
Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
Abby B. Siegel, E. Cohen, Allyson J. Ocean, Deborah Lehrer, Alec Goldenberg, Jennifer J. Knox, Helen Chen, Sean Clark-Garvey, Alan Weinberg, John Mandeli, Paul J. Christos, Madhu Mazumdar, E Popa, Robert S. Brown, Shahin Rafii, Jonathan D. Schwartz
Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis
Sasan Roayaie, Jonathan D. Schwartz, Max W. Sung, Sukru Emre, Charles M. Miller, Gabriel Gondolesi, Nancy Krieger, Myron Schwartz